| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.904 | 0.003 | 0.904 | Platelet aggregation inhibitor | 0.833 0.004 CID_154699804 0.858 0.004 CID_182017 | ||
| 0.902 | 0.004 | 0.902 | Anticonvulsant | 0.486 0.013 CID_154699804 0.694 0.005 CID_182017 | ||
| 0.889 | 0.003 | 0.889 | Platelet activating factor antagonist | 0.766 0.004 CID_154699804 0.819 0.003 CID_182017 | ||
| 0.809 | 0.001 | 0.809 | Benzodiazepine agonist | 0.194 0.005 CID_154699804 0.6 0.002 CID_182017 | ||
| 0.751 | 0.002 | 0.751 | GABA A receptor antagonist | 0.207 0.005 CID_154699804 0.497 0.003 CID_182017 | ||
| 0.746 | 0.003 | 0.746 | GABA receptor agonist | 0.437 0.004 CID_154699804 0.588 0.003 CID_182017 | ||
| 0.738 | 0.003 | 0.738 | GABA receptor antagonist | 0.216 0.005 CID_154699804 0.486 0.003 CID_182017 | ||
| 0.734 | 0.003 | 0.734 | GABA C receptor rho-3 antagonist | 0.441 0.045 CID_154699804 0.628 0.005 CID_182017 | ||
| 0.671 | 0.005 | 0.671 | Psychostimulant | 0.497 0.011 CID_154699804 0.528 0.009 CID_182017 | ||
| 0.427 | 0.004 | 0.427 | Vasopressin 1 antagonist | 0.091 0.01 CID_154699804 0.118 0.008 CID_182017 | ||
| 0.501 | 0.087 | 0.501 | Antiinflammatory | 0.29 0.225 CID_154699804 | ||
| 0.388 | 0.018 | 0.388 | Cyclic AMP phosphodiesterase inhibitor | 0.198 0.095 CID_154699804 0.26 0.059 CID_182017 | ||
| 0.365 | 0.003 | 0.365 | Vasopressin 1A antagonist | 0.083 0.007 CID_154699804 0.089 0.006 CID_182017 | ||
| 0.36 | 0.004 | 0.36 | GABA A receptor agonist | 0.102 0.036 CID_154699804 0.098 0.04 CID_182017 | ||
| 0.357 | 0.004 | 0.357 | Antidiuretic hormone antagonist | 0.098 0.013 CID_154699804 0.126 0.009 CID_182017 | ||
| 0.338 | 0.004 | 0.338 | GABA C receptor rho-2 antagonist | 0.193 0.033 CID_154699804 0.252 0.011 CID_182017 | ||
| 0.322 | 0.003 | 0.322 | Bromodomain-containing protein 4 inhibitor | 0.059 0.033 CID_154699804 0.222 0.004 CID_182017 | ||
| 0.274 | 0.003 | 0.274 | Bromodomain-containing protein 2 inhibitor | 0.085 0.065 CID_154699804 0.186 0.004 CID_182017 | ||
| 0.266 | 0.002 | 0.266 | Bromodomain-containing protein 3 inhibitor | 0.096 0.005 CID_154699804 0.223 0.003 CID_182017 | ||
| 0.22 | 0.004 | 0.22 | Oxytocin antagonist | 0.161 0.005 CID_154699804 0.119 0.009 CID_182017 | ||
| 0.212 | 0.007 | 0.212 | Interleukin 2 antagonist | 0.156 0.016 CID_182017 | ||
| 0.175 | 0.013 | 0.175 | GABA C receptor rho-1 antagonist | 0.105 0.055 CID_154699804 0.119 0.041 CID_182017 | ||
| 0.18 | 0.033 | 0.18 | Glutamate receptor antagonist | |||
| 0.164 | 0.023 | 0.164 | GABA C receptor antagonist | 0.101 0.076 CID_154699804 0.116 0.057 CID_182017 | ||
| 0.166 | 0.031 | 0.166 | Pregnane X receptor agonist | 0.137 0.081 CID_182017 | ||
| 0.228 | 0.097 | 0.228 | Cardiotonic | |||
| 0.225 | 0.112 | 0.225 | Gastrin inhibitor | |||
| 0.12 | 0.008 | 0.12 | Phosphodiesterase II inhibitor | 0.058 0.035 CID_182017 | ||
| 0.138 | 0.026 | 0.138 | Phosphodiesterase 7B inhibitor | 0.099 0.057 CID_182017 | ||
| 0.114 | 0.004 | 0.114 | Benzodiazepine antagonist | 0.069 0.007 CID_182017 | ||
| 0.115 | 0.007 | 0.115 | Cholecystokinin A antagonist | |||
| 0.111 | 0.007 | 0.111 | Phosphodiesterase 2A inhibitor | 0.051 0.033 CID_182017 | ||
| 0.114 | 0.018 | 0.114 | Protein kinase B beta inhibitor | 0.091 0.032 CID_154699804 0.109 0.02 CID_182017 | ||
| 0.102 | 0.008 | 0.102 | Cholecystokinin antagonist | 0.039 0.03 CID_182017 | ||
| 0.102 | 0.01 | 0.102 | Phosphodiesterase 1C inhibitor | 0.069 0.03 CID_182017 | ||
| 0.139 | 0.05 | 0.139 | Cholesterol synthesis inhibitor | 0.12 0.065 CID_182017 | ||
| 0.092 | 0.009 | 0.092 | Nicotinic acid receptor 1 agonist | 0.064 0.015 CID_182017 | ||
| 0.298 | 0.215 | 0.298 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.148 | 0.066 | 0.148 | MAP kinase kinase 4 inhibitor | 0.137 0.092 CID_154699804 0.143 0.077 CID_182017 | ||
| 0.092 | 0.012 | 0.092 | Phosphodiesterase 1A inhibitor | 0.058 0.046 CID_182017 | ||
| 0.098 | 0.022 | 0.098 | Purinergic P2 antagonist | |||
| 0.086 | 0.012 | 0.086 | Purinergic P2X antagonist | |||
| 0.138 | 0.069 | 0.138 | Nav1.6 sodium channel blocker | 0.132 0.078 CID_154699804 0.138 0.069 CID_182017 | ||
| 0.209 | 0.142 | 0.219 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.219 0.117 CID_154699804 | CID_154699804 | |
| 0.086 | 0.019 | 0.086 | Phosphodiesterase 1B inhibitor | |||
| 0.099 | 0.035 | 0.099 | Glutamate (mGluR) antagonist | |||
| 0.132 | 0.071 | 0.132 | Sodium channel (voltage-gated) blocker | |||
| 0.079 | 0.018 | 0.079 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.101 | 0.043 | 0.101 | Phosphodiesterase I inhibitor | |||
| 0.066 | 0.008 | 0.066 | Purinergic P2X7 antagonist | |||
| 0.075 | 0.019 | 0.075 | AMPA receptor antagonist | 0.042 0.04 CID_154699804 0.053 0.029 CID_182017 | ||
| 0.084 | 0.034 | 0.084 | Glutamate (mGluR group I) antagonist | |||
| 0.068 | 0.018 | 0.068 | Glutamate (mGluR5) antagonist | |||
| 0.063 | 0.013 | 0.063 | Benzodiazepine inverse agonist | 0.047 0.031 CID_154699804 | ||
| 0.112 | 0.065 | 0.112 | MAP kinase 13 inhibitor | 0.104 0.075 CID_182017 | ||
| 0.057 | 0.012 | 0.057 | Vasopressin 2 antagonist | |||
| 0.088 | 0.046 | 0.088 | Glycine receptor antagonist | 0.078 0.06 CID_182017 | ||
| 0.122 | 0.081 | 0.122 | Phosphodiesterase inhibitor | |||
| 0.081 | 0.04 | 0.081 | GABA B receptor agonist | 0.07 0.069 CID_182017 | ||
| 0.087 | 0.05 | 0.087 | Histamine H1 receptor antagonist | |||
| 0.053 | 0.016 | 0.053 | GABA B receptor antagonist | |||
| 0.234 | 0.198 | 0.234 | Analgesic | |||
| 0.105 | 0.07 | 0.105 | 5 Hydroxytryptamine 3A agonist | |||
| 0.043 | 0.011 | 0.082 | Benzodiazepine receptor peripheral-type antagonist | 0.066 0.004 CID_154699804 0.082 0.004 CID_182017 | CID_182017 | |
| 0.086 | 0.054 | 0.091 | mTOR complex 2 inhibitor | 0.091 0.045 CID_154699804 0.082 0.064 CID_182017 | CID_154699804 | |
| 0.049 | 0.018 | 0.049 | Alpha 1L adrenoreceptor agonist | |||
| 0.082 | 0.053 | 0.082 | Phosphodiesterase 3A inhibitor | |||
| 0.05 | 0.022 | 0.05 | Parathyroid hormone antagonist | 0.043 0.037 CID_182017 | ||
| 0.089 | 0.062 | 0.089 | Potassium channel activator | |||
| 0.071 | 0.044 | 0.071 | MAP kinase kinase 8 inhibitor | |||
| 0.127 | 0.102 | 0.127 | Thrombolytic | |||
| 0.142 | 0.123 | 0.244 | Anesthetic general | 0.192 0.079 CID_154699804 0.244 0.053 CID_182017 | CID_182017 | |
| 0.122 | 0.103 | 0.122 | Diuretic | |||
| 0.231 | 0.216 | 0.231 | MAP kinase kinase 6 inhibitor | |||
| 0.025 | 0.013 | 0.025 | Corticotropin releasing factor 1 receptor antagonist | |||
| 0.039 | 0.029 | 0.039 | CF transmembrane conductance regulator antagonist | 0.039 0.03 CID_182017 | ||
| 0.121 | 0.112 | 0.121 | Heat shock protein 90 antagonist | |||
| 0.194 | 0.185 | 0.194 | Antithrombotic | |||
| 0.044 | 0.036 | 0.044 | Purinergic P2X4 antagonist | |||
| 0.085 | 0.078 | 0.085 | DNA directed RNA polymerase inhibitor | |||
| 0.078 | 0.072 | 0.078 | CC chemokine 5 receptor agonist | |||
| 0.064 | 0.06 | 0.064 | MDM2 inhibitor | |||
| 0.036 | 0.034 | 0.036 | 5 Hydroxytryptamine 2B agonist | |||
| 0.054 | 0.053 | 0.054 | 5 Hydroxytryptamine 2A agonist | |||
| 0.06 | 0.059 | 0.06 | Calcium channel P-type blocker | |||
| 0.072 | 0.074 | 0.082 | MAP kinase kinase 7 inhibitor | 0.082 0.04 CID_154699804 | CID_154699804 | |
| 0.097 | 0.134 | 0.186 | Cytidine deaminase inhibitor | 0.186 0.054 CID_154699804 0.164 0.066 CID_182017 | CID_154699804 | |
| 0.045 | 0.09 | 0.094 | Cyclin B3 inhibitor | 0.094 0.031 CID_182017 | CID_182017 | |
| 0.063 | 0.147 | 0.086 | Protein kinase C zeta inhibitor | 0.086 0.073 CID_154699804 0.084 0.078 CID_182017 | CID_154699804 | |
| 0.043 | 0.156 | 0.06 | Kallikrein 7 inhibitor | 0.06 0.055 CID_182017 | CID_182017 | |
| 0.054 | 0.174 | 0.095 | NADH dehydrogenase inhibitor | 0.095 0.049 CID_154699804 | CID_154699804 | |
| 0.072 | 0.201 | 0.099 | Interleukin 8 antagonist | 0.099 0.098 CID_182017 | CID_182017 | |
| 0.128 | 0.294 | 0.325 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.325 0.048 CID_154699804 0.306 0.06 CID_182017 | CID_154699804 | |
| 0.022 | 0.191 | 0.082 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.082 0.02 CID_154699804 | CID_154699804 | |
| 0.024 | 0.196 | 0.064 | Protein kinase C beta inhibitor | 0.064 0.06 CID_154699804 | CID_154699804 | |
| 0.038 | 0.269 | 0.096 | Protein kinase C gamma inhibitor | 0.096 0.085 CID_154699804 | CID_154699804 | |
| 0.094 | 0.353 | 0.155 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.155 0.137 CID_154699804 | CID_154699804 | |
| 0.043 | 0.323 | 0.092 | Nav1.1 sodium channel blocker | 0.092 0.076 CID_154699804 | CID_154699804 | |
| 0.015 | 0.306 | 0.068 | Protein kinase C eta inhibitor | 0.068 0.03 CID_154699804 | CID_154699804 | |
| 0.046 | 0.359 | 0.09 | Adenylate kinase inhibitor | 0.09 0.088 CID_154699804 | CID_154699804 | |
| 0.034 | 0.35 | 0.105 | Alpha-N-acetylglucosaminidase inhibitor | 0.105 0.094 CID_154699804 | CID_154699804 | |
| 0.07 | 0.405 | 0.222 | DNA synthesis inhibitor | 0.222 0.092 CID_154699804 | CID_154699804 | |
| 0.029 | 0.378 | 0.112 | Protein kinase C nu inhibitor | 0.112 0.102 CID_154699804 | CID_154699804 | |
| 0.023 | 0.374 | 0.115 | Protein kinase C mu inhibitor | 0.115 0.045 CID_154699804 0.085 0.073 CID_182017 | CID_154699804 | |
| 0.054 | 0.424 | 0.17 | DNA damaging | 0.17 0.145 CID_154699804 | CID_154699804 | |
| 0.099 | 0.625 | 0.309 | Calcium channel L-type activator | 0.309 0.15 CID_154699804 | CID_154699804 | |
| 0.002 | 0.948 | 0.038 | 1,3-Beta-glucan synthase inhibitor | 0.038 0.004 CID_154699804 0.034 0.008 CID_182017 | CID_154699804 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |